A newly established venture capital firm headquartered in Western Europe is tied with a dedicated life sciences consulting firm with multiple offices throughout USA, Europe, and Asia. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.
The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.
The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply